Do you find our website to be helpful?
Yes   No

ESCAPE: Changing the way stroke patients are treated

Blog image

The ESCAPE trial is a testament to the importance of research and innovation in the evolution of treatment options for patients.

Our neurointerventional surgeons were key contributors to this landmark clinical trial that demonstrated the benefits of endovascular treatment compared to conventional treatment for patients with acute ischemic stroke. The results were published in the New England Journal of Medicine in 2015. The benefits were so significant that the study was halted early because of efficacy. Stroke is a disease that severely impairs functional independence or takes the lives of approximately 60-80% of patients within 90 days after onset. This study demonstrated that rapid endovascular treatment significantly improves functional outcomes and reduces mortality.

Author
Alicia Drew, MSN, RN, CNL Director, Research & Physician Services

You Might Also Enjoy...

COMPASS Trial: A Direct Aspiration First Pass Technique

Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of Acute Ischemic Stroke (AIS) within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours.

We Are Committed to Clinical Research

RIA has a rich history of participation in clinical research and innovation dating back to the 1980s.  Many of our physicians believe it is important to contribute to science and advance medicine.